NFE2L2 and pancreatic neoplasm: Taken together, these results demonstrate that NSLC01 is active against clinically relevant pancreatic cancer cell lines and ex vivo-cultured tumor tissues, with cytotoxic effects based on NRF2/NQO1 activation.